And the results of that trial were published last August (2017): Title: Exenatide once weekly versus placebo in Parkinsons disease: a randomised, double-blind, placebo-controlled trial Authors: Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T Journal: Lancet 2017 Aug 3
Even if the FDA adopts the recommendation, BPC-157 would remain prescription-only, available through a licensed pharmacy and requiring a clinician to weigh a patients history against still-limited evidence
The strong performance was primarily driven by increased demand for pediatric vaccinations in the US, attributed to favorable timing of government purchases and higher patient demand in the private market
doi: 10.1056/NEJMoa1607427